Table 6.

Strategies for development of anti-CD25 monoclonal antibody (mAb)

Strategy	Potential benefit for anti-CD25 mAb
1) Develop a human MAb	Less immunogenic
2) Change IgG isotype	Modulation of Fc functions
3) Change epitope	Alter binding and/or IL-2 blockade
4) Change affinity	Change kinetics and duration of binding
5) Change glycosylation	Alter ADCC or CDC function
6) Prepare Fab or Fab’2 fragments	Eliminate Fc functions and cytotoxicity

Fc = fragment crystallizable region; IL = interleukin; ADCC = antibody-dependent cell-mediated cytotoxicity^; CDC = complement-dependent cytotoxicity; Fab = fragment antigen binding